Compare PKOH & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKOH | CLLS |
|---|---|---|
| Founded | 1907 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.3M | 299.0M |
| IPO Year | N/A | 2007 |
| Metric | PKOH | CLLS |
|---|---|---|
| Price | $21.21 | $4.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 32.9K | ★ 124.5K |
| Earning Date | 11-05-2025 | 11-07-2025 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | ★ 30.26 | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $1,592,500,000.00 | $82,551,000.00 |
| Revenue This Year | $0.23 | N/A |
| Revenue Next Year | $3.07 | $58.00 |
| P/E Ratio | $9.94 | ★ N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $15.52 | $1.10 |
| 52 Week High | $33.19 | $5.48 |
| Indicator | PKOH | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 60.73 | 69.02 |
| Support Level | $18.69 | $4.90 |
| Resistance Level | $20.50 | $5.35 |
| Average True Range (ATR) | 0.74 | 0.28 |
| MACD | 0.19 | 0.14 |
| Stochastic Oscillator | 98.20 | 85.56 |
Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.